Stay updated with breaking news from Active Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Annual General Meeting of Active Biotech was held on May 19, 2022. Due to the situation resulting from the Corona virus, the Meeting was carried out through postal voting, without any physical attendance.
Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis. "The
Active Biotech's Annual Report 2021 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Download as PDF Lund, April 28, 2022 Active
Investegate announcements from Active Biotech, Active Biotech strengthens the patent protection for laquinimod in eye disorders
Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech's patent related to use of laquinimod as